Psychedelic stocks are publicly traded companies focused on developing and commercializing medicines derived from psychedelic compounds for therapeutic applications. These firms engage in drug discovery, clinical trials and regulatory approval processes to bring psychedelic-assisted therapies to market for mental health and neurological conditions including depression, anxiety disorders, PTSD and substance use disorders.
Cybin is a biopharmaceutical leader developing innovative psychedelic-based therapeutics for mental health, including depression and anxiety disorders.
MindMed pioneers psychedelic-inspired therapies to address mental health disorders, aiming to transform treatment for anxiety, ADHD, and autism spectrum disorder.
AtaiBeckley develops and advances clinical-stage psychedelic-based and neuropharmacology therapies for mental health conditions, including treatment-resistant depression.
Compass Pathways pioneers evidence-based mental health innovations, developing psilocybin therapies for treatment-resistant depression and other serious conditions.
MIRA Pharmaceuticals develops novel oral ketamine and marijuana analogs to treat neurologic and neuropsychiatric disorders.
Bionomics develops novel ion channel modulators for treating serious central nervous system disorders like anxiety and PTSD.
PharmAla Biotech is a Canadian company specializing in the research, development, and manufacturing of clinical-grade MDMA and novel MDXX compounds.
Silo Pharma develops novel therapeutics for PTSD, chronic pain, and CNS diseases, merging traditional and psychedelic research to address unmet medical needs.
Psychedelic stocks represent publicly traded companies developing medicines derived from psychedelic compounds such as psilocybin, MDMA, ketamine and LSD for therapeutic use. These firms operate across drug discovery, clinical trial execution and treatment delivery, targeting mental health conditions including depression, PTSD, anxiety disorders and substance use disorders.
The psychedelic medicine sector emerged from decades of academic research demonstrating that controlled psychedelic therapy can produce meaningful outcomes in patients who have not responded to conventional treatments. Clinical programs focus on addressing the gap left by traditional psychiatric medications, which often require daily use and can carry side effects or limited efficacy. Psychedelic-assisted therapies typically involve supervised dosing sessions combined with structured psychological support.
Companies in this space include pharmaceutical developers conducting FDA-regulated trials, clinical research organizations managing psychedelic studies and platforms building infrastructure for legal therapeutic access. The sector overlaps with broader biotechnology and pharmaceutical innovation, as firms navigate regulatory approval processes similar to those governing other investigational drugs. Mental health treatment represents a significant area of medical need and psychedelic stocks attract attention from those tracking emerging longevity and wellness trends alongside novel medical interventions.
Psychedelic stocks offer exposure to a specialized segment of drug development focused on conditions with high unmet medical need. Companies face regulatory uncertainty, lengthy clinical timelines and scientific validation requirements common across early-stage pharmaceutical ventures. The sector reflects the broader evolution in mental health care, where new mechanisms of action and treatment paradigms are being tested.
Join top talent at the world's most respected institutions, companies, and venture capital funds.
